|
|
|
| Effect of Huachansu (Cinobufacini)Capsule Combined with Hepatic Arterial Infusion Chemoembolization in Patients with Liver Cancer |
| YE Lu, YANG Li, MU Dan,et al |
| Oncology Department, No.416 Hospital of Ministry of Nuclear Industry, Chengdu City, Sichuan Province, 610051 |
|
|
|
Abstract 【Objective】 To investigate the effect of cinobufacini capsules combined with hepatic arterial infusion chemoembolization in patients with liver cancer. 【Methods】Sixty-eight patients with hepatocellular carcinoma treated in our hospital were randomly divided into group A and group B, 34 cases in each. On the basis of TACE, the Group A was treated with the cinobufacini capsules, and the Group B underwent hepatic artery TACE only. The changes of plasma fibrinogen (FIB), tumor markers, clinical efficacy and quality of life were compared between the two groups before and after treatment.【Results】 There was no significant difference in FIB content between the two groups before treatment (P>0.05), and no significant difference existed in FIB content in the Group A before and after treatment (P>0.05) ; The FIB content in the group B was significantly higher than that before treatment, and was even significantly higher than that in the Group A (mean P<0.05). After treatment, the Cytokeratin 19 fragments, CEA, NSE concentrations of the two groups were significantly lower than those before treatment, and the difference was significant (P<0.05). It showed no significant difference between the three indexes of the Group A and the Group B after treatment (P>0.05).The disease control rate of the Group A was 77.5% (26/34), which was significantly higher than that of the Group B 67.6% (23/34); The incidence of pain and fatigue in the Group A was significantly lower than that in the Group B (P<0.05).【Conclusion】Cinobufacini capsules combined with TACE can improve the hypercoagulable state of blood in patients, which is beneficial for the treatment of cancer, improve the control rate of disease and improve the life quality of patients.
|
|
Received: 04 January 2017
|
|
|
|
|
|
[1] 武中林,李智岗,吴晓云等.经导管肝动脉栓塞与肝动脉灌注化疗栓塞在原发性肝癌介入治疗中的远期疗效比较[J].中国全科医学,2016,19(11):1292-1296.
[2] 杨柳.华蟾素胶囊治疗肿瘤患者顽固性呃逆的临床观察[J].中国药房,2016,27(24):3348-3349,3350.
[3] 武中林.肝转移瘤血供对肝动脉灌注化疗栓塞近期疗效的影响[J].河北医科大学学报,2015,36(5):497-500.
[4] 仇蓉.临终关怀对改善恶性肿瘤晚期患者生命质量的影响[J].齐鲁护理杂志,2012,18(16):59-60.
[5] 韦艳,卢珩,王荣荣,等.华蟾素注射液抗肝癌细胞多药耐药性的蛋白质组学分析[J].基础医学与临床,2014,34(6):814-818.
[6] 黄媛,陈建魁,于农,等.肺癌患者血小板计数与血浆纤维蛋白原水平变化与肿瘤转移的关系[J].国际检验医学杂志,2013,34(19):2532-2533.
[7] 杨新波.华蟾素胶囊治疗癌性疼痛的临床疗效观察[J].中国医药导刊,2014,16(3):478-479,481.
[8] 施俊,秦志丰,王晓伟,等.消痰散结中医治疗方案用于胃癌术后临床观察[J].中国中医药信息杂志,2011,18(10):14-17.
(本文编辑:王沪湘) [收稿日期] 2017-01-04
|
|
|
|
2017, Vol. 34 
